BioInvent International AB logo

BINV BTA - BioInvent International AB News Story

SEK1.7 0.0  0.0%

Last Trade - 12/08/20

Sector
Healthcare
Size
Small Cap
Market Cap £285.1m
Enterprise Value £150.1m
Revenue £11.8m
Position in Universe th / 1838

BRIEF-Bioinvent Gets IND Approval For Phase I/IIa Trial Of Anti-TNFR2 Antibody BI-1808

Wed 7th April, 2021 7:38am
April 7 (Reuters) - BioInvent International AB  BINV.ST :
    * BIOINVENT RECEIVES IND APPROVAL FOR PHASE I/IIA TRIAL OF
ANTI-TNFR2 ANTIBODY BI-1808
    * U.S. FOOD AND DRUG ADMINISTRATION (FDA) HAS APPROVED
INVESTIGATIONAL NEW DRUG (IND) FOR PHASE I/IIA CLINICAL STUDY OF
IMMUNO-MODULATORY ANTI-TNFR2 ANTIBODY BI-1808

Source text for Eikon:  ID:nWkrbxnSSd 
Further company coverage:  BINV.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.